A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial

Publisher Website
Google Scholar
Abstract
This open, prospective study was conducted to compare ZOLADEX® (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer. Sixtyseven patients were allocated to receive 3.6 mg of ZOLADEX® every 28 days by subcutaneous injection (n=48) or 3 mg of DES daily by oral administration (n=19). Median serum levels of testosterone were reduced to castrate levels (<50 ng/dl) within one month of therapy in each group and remained so for up to 120 weeks. According to modified criteria of the National Prostatic Cancer Project, 88% of patients in the ZOLADEX® group and 84% in the DES group were objective responders. Time to treatment failure and survival were not significantly different between groups, yet the confidence limits for the hazard ratios were wide. ZOLADEX® was better tolerated than DES. We conclude that ZOLADEX® is an alternative to DES in patients with stage D2 prostate cancer.